Wockhardt Ltd

Wockhardt Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 March 2026, providing investors with the most up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating technical parameters and underwhelming returns relative to the Sensex, paints a challenging outlook for investors as of early March 2026.

Wockhardt Ltd’s investment rating has been upgraded from Sell to Strong Sell as of 23 February 2026, reflecting a nuanced shift in its financial and technical outlook. Despite notable improvements in quarterly profitability and financial trends, the company continues to face valuation and long-term fundamental challenges that temper investor enthusiasm.

Wockhardt Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance as of February 2026. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock exhibits a complex interplay of technical indicators, reflecting both bullish and bearish signals across different timeframes. This nuanced technical landscape warrants a detailed examination for investors seeking clarity amid the volatility.

Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable turnaround in its recent quarterly financial performance. The company’s December 2025 quarter results reveal significant growth in profitability and sales, signalling a positive shift in its financial trend despite a challenging market environment and a recent downgrade in its Mojo Grade to Sell.

Wockhardt Ltd’s stock price momentum has shifted from mildly bullish to a sideways trend, reflecting a complex interplay of technical indicators. Despite a modest day change of 0.07%, the pharmaceutical company’s technical parameters reveal a nuanced picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. Investors should carefully analyse these developments amid the stock’s recent performance relative to the broader market.

Wockhardt Ltd has experienced a subtle but notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish one on weekly charts, despite mixed signals across monthly indicators. The stock’s recent price action, combined with evolving technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, suggests a nuanced outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Wockhardt Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 12 Feb 2026, reflecting a complex interplay of financial performance, valuation concerns, and technical indicators. Despite recent positive quarterly results, the company faces challenges in long-term fundamentals and market sentiment, prompting a cautious stance from analysts.

Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, transitioning from a mildly bullish to a mildly bearish trend. This change is underscored by a complex interplay of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling a cautious outlook for investors amid recent price fluctuations.

Wockhardt Ltd has demonstrated robust financial performance in the December 2025 quarter, marking a notable shift from a previously very positive to a positive financial trend. The pharmaceutical company’s latest results reveal significant growth in profitability and sales, alongside improved operational efficiency, despite a modest downgrade in its overall mojo grade to Sell.

Wockhardt Ltd., a global pharmaceutical and biotechnology enterprise, reported consolidated net profit of ₹59.00 crores for Q3 FY26, marking a sharp sequential decline of 24.36% from the preceding quarter's ₹78.00 crores, though delivering a remarkable 321.43% year-on-year surge from ₹14.00 crores in Q3 FY25. The ₹22,734 crore market capitalisation company's shares traded at ₹1,428.70 on February 10, 2026, reflecting a modest 1.09% gain for the day but continuing to struggle 23.60% below its 52-week high of ₹1,870.00.

Wockhardt Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a modest day gain of 1.07%, the stock’s technical profile reveals a nuanced outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Wockhardt Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 January 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 03 February 2026, providing investors with the most up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Wockhardt Ltd witnessed a significant gap up at the opening bell on 3 Feb 2026, surging by 5.98% compared to its previous close. This strong start underscores a positive market sentiment towards the pharmaceutical company, which outperformed its sector and broader market indices during the day.

Wockhardt Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 January 2026, providing investors with the latest insights into its performance and outlook.